NASDAQ · RLMD
Relmada Therapeutics, Inc.
$3.44+$0.09 (+2.69%)
Relmada Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.0% below the high.
Loading market information…
NASDAQ · LITS · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Lite Strategy, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.23% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Lite Strategy, Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$3.12. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Lite Strategy, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | Nov 12, 2024 | -$1.20+29.41% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q4 2024 | Sep 19, 2024 | -$2.76-96.21% vs estimate | $0.00-100.0% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.44+$0.09 (+2.69%)
Relmada Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.0% below the high.
$7.80-$0.19 (-2.32%)
Immunic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.28% below the high.
$6.64+$0.24 (+3.75%)
Nutriband Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.75% below the high.
$1.76-$0.03 (-1.68%)
Acrivon Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 50.56% below the high.
$1.35-$0.03 (-2.17%)
PMV Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.32% below the high.
$1.94-$0.05 (-2.51%)
XBiotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.6% below the high.
$1.10+$0.04 (+3.77%)
Werewolf Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.78% below the high.
$3.58-$0.23 (-6.04%)
Adicet Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.38% below the high.
